IPP Bureau

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL
Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

By IPP Bureau - July 15, 2025

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

By IPP Bureau - July 15, 2025

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,

India launches nutraceutical trade expo ‘Bharat Nutraverse’
India launches nutraceutical trade expo ‘Bharat Nutraverse’

By IPP Bureau - July 15, 2025

India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025

Lilly partners with API to launch ‘Obesity Gurukul’ in India
Lilly partners with API to launch ‘Obesity Gurukul’ in India

By IPP Bureau - July 15, 2025

The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities

PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization
PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization

By IPP Bureau - July 15, 2025

The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development

WHO, ITU, and WIPO release new report on AI use in traditional medicine
WHO, ITU, and WIPO release new report on AI use in traditional medicine

By IPP Bureau - July 15, 2025

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly
Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly

By IPP Bureau - July 15, 2025

The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

By IPP Bureau - July 15, 2025

Capricor’s BLA for Deramiocel received Priority Review in March 2025

Zydus receives final approval from USFDA for Celecoxib Capsules
Zydus receives final approval from USFDA for Celecoxib Capsules

By IPP Bureau - July 15, 2025

Celecoxib is a nonsteroidal anti-inflammatory drug

Cupid invests in GII Healthcare Investment
Cupid invests in GII Healthcare Investment

By IPP Bureau - July 15, 2025

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India

Merck launches AAW workstation to advance lab automation
Merck launches AAW workstation to advance lab automation

By IPP Bureau - July 15, 2025

New platform powered by Opentrons expands lab automation to accelerate scientific discovery

Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata

By IPP Bureau - July 14, 2025

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

By IPP Bureau - July 14, 2025

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

Sun Pharma settles patent litigation with Incyte
Sun Pharma settles patent litigation with Incyte

By IPP Bureau - July 14, 2025

Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill

By IPP Bureau - July 14, 2025

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally

Latest Stories

Interviews

Packaging